Navigation Links
ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
Date:6/13/2008

mg product is a white oval tablet with "60" on one side, and "E" on the reverse. The 30 mg product is a pink oval tablet with "30" on one side, and "E" on the reverse.

Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-321-1705, or fax to ETHEX Customer Service at 314-646-3751 or sent via email to: customer-service@ethex.com with representatives available Monday through Friday, 8 am to 5 pm CDT.

ETHEX Corporation has initiated recall notifications to wholesalers and retailers who have received any inventory of the recalled lots of this product with instructions for returning the recalled product and, if they have not already done so, they are urged to contact the number above regarding procedures for returning the recalled product. If consumers have any questions about the recall, they should call the number above, their physician, their pharmacist or other health care provider.

This recall is being conducted with the knowledge of the Food and Drug Administration (FDA).

Any adverse reactions experienced with the use of this product, and/or quality problems may also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at http://www.fda.gov/medwatch.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim", "believe", "projects", "anticipates", "commit", "intend", "estimate", "will", "should", "could" and other expressi
'/>"/>

SOURCE ETHEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genaera Corporation to Present at BIO Business Forum
2. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
3. Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
4. Environmental Tectonics Corporations BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers
5. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
6. DURECT Corporation to Participate in Upcoming Healthcare Conferences
7. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
8. Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
9. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
10. David M. Stout Joins NanoBio Corporations Board of Directors
11. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... 16, 2015 Dana-Farber Cancer Institute ... and Resolution Bioscience, Inc. today announced the successful ... novel, blood-based, clinic ready, Next Generation Sequencing (NGS) ... collaboration is the first to demonstrate the successful ... fusions in blinded plasma samples and highlights the ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... 2011 RiverVest Venture Partners®, a venture capital ... companies, today announced that John McKearn, Ph.D., has ... Dr. McKearn joined RiverVest as Venture Partner in ... pharmaceutical research and development as former president and ...
... 3, 2011 Cynosure, Inc. (NASDAQ: CYNO ) today ... Revenues for the first quarter of 2011 increased ... period of 2010.   Net loss for the first quarter of ... compared with a net loss of $2.8 million, or $0.22 per ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... The net income for the first quarter ended ... loss of $14.1 million during the same period in 2010. ... was related primarily to the $34.2 million in collaboration revenue ...
Cached Biology Technology:John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners 2Cynosure Reports Financial Results for the First Quarter of 2011 2Cynosure Reports Financial Results for the First Quarter of 2011 3Cynosure Reports Financial Results for the First Quarter of 2011 4Cynosure Reports Financial Results for the First Quarter of 2011 5Cynosure Reports Financial Results for the First Quarter of 2011 6MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... latest research discoveries on diabetes, obesity, endocrine-disrupting chemicals, adolescent health ... press conferences at ENDO 2013: The 95th Annual Meeting & ... Saturday, June 15 Adolescent Health ... used to help teens with conditions including eating disorders and ...
... 2013The Roy J. Carver Charitable Trust has awarded a ... at the University of Illinois at Urbana-Champaign. Under the ... Investigator Dr. Christopher Rao, the grant will be disbursed ... for a new research theme devoted to the new ...
... oceans absorb about 25 percent of the carbon dioxide ... they have taken up about half of the man-made ... seen with the naked eye, make this valuable service ... seawater, various species convert it to organic carbon and ...
Cached Biology News:Roy J. Carver Charitable Trust funds new research focus at Institute for Genomic Biology 2Fast-sinking jellyfish could boost the oceans' uptake of carbon dioxide 2Fast-sinking jellyfish could boost the oceans' uptake of carbon dioxide 3
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
... RNAi Services offer you a full ... studies. B-Bridges advanced design parameters, effective ... ensure that you obtain quality results ... Design Service utilizes their proprietary B-Algo ...
Biology Products: